Journal of Surgical Oncology 9: 1-14 (1977)
In Memoriam: Mary Stults Sherman, M.D. It is indeed a privilege to provide these comments as a preface to a lecture dedicated to the memory of the work of Dr. Mary Stults Sherman. Those of us who knew her share the belief that she was a worthy prototype of the professional woman representative of the present-day women’s equal rights advocates. I am reminded of the fact that when Mary Sherman began her career there were only two other women orthopaedists in the entire country. Orthopaedics is a demanding specialty requiring stability, a background of knowledge fundamental for research, and sheer physical strength to perform surgery. All of these things she accomplished without giving or asking special quarter; she achieved a degree of professional recognition in orthopedic surgery matched by few in the field. Her career in medicine and orthopaedic surgery came after she had taught modern language for a short time. Inspired by Dr. Dallas B. Phemister and Dr. C. Howard Hatcher at the University of Chicago, she became interested in bone pathology and ultimately became a recognized authority in the field. She has written original and definitive articles on bone and joint pathology that are now considered standards on the subjects of femoral neck fractures, osteoid osteonia, psoriatic arthritis, osteomalacia, sickle cell disease, and particularly on bone tumors. Her publications were marked by a particular clarity of thought and exposition. A study of the pathological anatomy of talipes equinovarus with Dr. R. N. Irani resulted in a Kappa Delta Award in 1963 by the American Academy of Orthopaedic Surgery. Dr. Sherman had an exceptionally keen interest in bone tumors and as an orthopaedic surgeon and bone pathologist, her teaching stressed the correlative aspects of bone tumor diagnosis, including the clinical features, radiologic interpretation, and an accurate histologic interpret ation. She remained on the faculty at the University of Chicago for seven years after completing her residency program and then joined the Ochsner Foundation and Hospital in New Orleans, where she directed the Bone Pathology Laboratory. In addition, she received an appointment as an associate professor of orthopaedic surgery at Tulane University, maintaining a balance between clinical work, teaching, and research essential to an active academic career. Dr. Sherman participated in the work of many professional organizations. As chairman of the Pathology Committee of the American Academy of Orthopaedic Surgery and as advisor in pathology to the American Board of Orthopaedic Surgery, she gave particular emphasis and effort toward improving the teaching of bone pathology. She was a charter member of the Orthopaedic Research Society and actively contributed to the deliberations of many Gordon Research Conferences on Bones and Teeth. She championed the cause of improved orthopaedic care for underprivileged children in rural Louisiana, the Navajo Indian Reservation, and the Alaska Native Service. Her wide knowledge of literature, music, the arts, the plight of minority groups, and the world order through activity in the cause of Federal Union Now made her a stimulating intellectual conversationalist.
1
0 1977 Alan R. Liss, Inc., 150 Fifth Avenue, New York, NY 10011
MARY STULTS SHERMAN,M.D.
2
Copeland
In memory of her untimely passing, colleagues in New Orleans and throughout the orthopaedic and medical world contributed t o the Mary Sherman Memorial Orthopaedic Pathology Lecture and Seminar Fund. By this means they perpetuated the memory of an exceptionally outstanding individual who contributed so much to education and k-nowledge in orthopaedic pathology.
Michael Bonfiglio, M.D. Depart men t of Orthopaedic Surgery, University of Iowa, Iowa City .......................................................................................... ..........................................................................................
Recent Progress in Chemotherapy and lmmunotherapy of Sarcomas of Bony Origin, Both as Primary and Adjunctive Therapy .............................. ..............................
........................................................... ...........................................................
MURRAY M. COPELAND, M.D. Treatment for primary malignant tumors of bone, in the past several decades, has yielded uniformly poor results. Recent progress in chemotherapy and immunotherapy are detailed. An important advance in treating osteogenic sarcoma has been the application of adjuvant chemotherapy after initial amputation. CONPADRI-I and COMPADRI-I1 chemotherapy (a multiple drug approach) is discussed. Adriamycin in combination or alone has proved effective in treating osteogenic sarcoma. Ewing’s tumor is showing increased survival rates from radiation therapy alone, as well as by use of systemic adjuvant chemotherapy combined with local radiation. Adjuvant triple chemotherapy with radiotherapy has resulted in pronounced improvement in survival. Chondrosarcomas are largely chemotherapy-resistant. Immunotherapy in bone tumors still is in the experimental stage and investigations with immunotherapy are preliminary. It appears, however, that the immunological status of a patient definitely relates to prognosis. Through increased sophistication in specific Chemotherapy and magnitude of treatment, further advances in treatment of primary malignant bone tumors may be expected.
.......................................................................................... .......................................................................................... Key words: osteogenic sarcoma, Ewing’s tumor, chondrosarcoma, chemotherapy, immunotherapy *The Mary Sherman Lecture 1975, presented at the Mary S. Sherman Pathology Seminar and Lectureship, Dr. James S. Miles, Chairman, held at the University of Colorado Medical Center, Denver, Colorado, April 19. 1975. From The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas Address reprint requests t o Dr. Murray M. Copeland. Vice President, The University Cancer Foundation, The University of Texas System Cancer Center, Texas Medical Center, Houston, TX 77030.
In Memoriam: Mary Stults Sherman, M.D. It is indeed a privilege to provide these comments as a preface to a lecture dedicated to the memory of the work of Dr. Mary Stults Sherman. Those of us who knew her share the belief that she was a worthy prototype of the professional woman representative of the present-day women’s equal rights advocates. I am reminded of the fact that when Mary Sherman began her career there were only two other women orthopaedists in the entire country. Orthopaedics is a demanding specialty requiring stability, a background of knowledge fundamental for research, and sheer physical strength to perform surgery. All of these things she accomplished without giving or asking special quarter; she achieved a degree of professional recognition in orthopedic surgery matched by few in the field. Her career in medicine and orthopaedic surgery came after she had taught modern language for a short time. Inspired by Dr. Dallas B. Phemister and Dr. C. Howard Hatcher at the University of Chicago, she became interested in bone pathology and ultimately became a recognized authority in the field. She has written original and definitive articles on bone and joint pathology that are now considered standards on the subjects of femoral neck fractures, osteoid osteonia, psoriatic arthritis, osteomalacia, sickle cell disease, and particularly on bone tumors. Her publications were marked by a particular clarity of thought and exposition. A study of the pathological anatomy of talipes equinovarus with Dr. R. N. Irani resulted in a Kappa Delta Award in 1963 by the American Academy of Orthopaedic Surgery. Dr. Sherman had an exceptionally keen interest in bone tumors and as an orthopaedic surgeon and bone pathologist, her teaching stressed the correlative aspects of bone tumor diagnosis, including the clinical features, radiologic interpretation, and an accurate histologic interpret ation. She remained on the faculty at the University of Chicago for seven years after completing her residency program and then joined the Ochsner Foundation and Hospital in New Orleans, where she directed the Bone Pathology Laboratory. In addition, she received an appointment as an associate professor of orthopaedic surgery at Tulane University, maintaining a balance between clinical work, teaching, and research essential to an active academic career. Dr. Sherman participated in the work of many professional organizations. As chairman of the Pathology Committee of the American Academy of Orthopaedic Surgery and as advisor in pathology to the American Board of Orthopaedic Surgery, she gave particular emphasis and effort toward improving the teaching of bone pathology. She was a charter member of the Orthopaedic Research Society and actively contributed to the deliberations of many Gordon Research Conferences on Bones and Teeth. She championed the cause of improved orthopaedic care for underprivileged children in rural Louisiana, the Navajo Indian Reservation, and the Alaska Native Service. Her wide knowledge of literature, music, the arts, the plight of minority groups, and the world order through activity in the cause of Federal Union Now made her a stimulating intellectual conversationalist.
1
0 1977 Alan R. Liss, Inc., 150 Fifth Avenue, New York, NY 10011
MARY STULTS SHERMAN,M.D.
2
Copeland
In memory of her untimely passing, colleagues in New Orleans and throughout the orthopaedic and medical world contributed t o the Mary Sherman Memorial Orthopaedic Pathology Lecture and Seminar Fund. By this means they perpetuated the memory of an exceptionally outstanding individual who contributed so much to education and k-nowledge in orthopaedic pathology.
Michael Bonfiglio, M.D. Depart men t of Orthopaedic Surgery, University of Iowa, Iowa City .......................................................................................... ..........................................................................................
Recent Progress in Chemotherapy and lmmunotherapy of Sarcomas of Bony Origin, Both as Primary and Adjunctive Therapy .............................. ..............................
........................................................... ...........................................................
MURRAY M. COPELAND, M.D. Treatment for primary malignant tumors of bone, in the past several decades, has yielded uniformly poor results. Recent progress in chemotherapy and immunotherapy are detailed. An important advance in treating osteogenic sarcoma has been the application of adjuvant chemotherapy after initial amputation. CONPADRI-I and COMPADRI-I1 chemotherapy (a multiple drug approach) is discussed. Adriamycin in combination or alone has proved effective in treating osteogenic sarcoma. Ewing’s tumor is showing increased survival rates from radiation therapy alone, as well as by use of systemic adjuvant chemotherapy combined with local radiation. Adjuvant triple chemotherapy with radiotherapy has resulted in pronounced improvement in survival. Chondrosarcomas are largely chemotherapy-resistant. Immunotherapy in bone tumors still is in the experimental stage and investigations with immunotherapy are preliminary. It appears, however, that the immunological status of a patient definitely relates to prognosis. Through increased sophistication in specific Chemotherapy and magnitude of treatment, further advances in treatment of primary malignant bone tumors may be expected.
.......................................................................................... .......................................................................................... Key words: osteogenic sarcoma, Ewing’s tumor, chondrosarcoma, chemotherapy, immunotherapy *The Mary Sherman Lecture 1975, presented at the Mary S. Sherman Pathology Seminar and Lectureship, Dr. James S. Miles, Chairman, held at the University of Colorado Medical Center, Denver, Colorado, April 19. 1975. From The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas Address reprint requests t o Dr. Murray M. Copeland. Vice President, The University Cancer Foundation, The University of Texas System Cancer Center, Texas Medical Center, Houston, TX 77030.
